Enanta Pharmaceuticals Inc.'s EDP-938 hit both the primary and secondary endpoints in a Phase IIa study in respiratory syncytial virus (RSV), but a greater test likely awaits when the Boston-area firm seeks to repeat that success in a real-world setting.
Enanta Hopes To Succeed In RSV With N-Protein Inhibition Approach
Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.
More from Clinical Trials
More from R&D
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.